Cannabidiol - Zynerba Pharmaceuticals

Drug Profile

Cannabidiol - Zynerba Pharmaceuticals

Alternative Names: Cannabidiol transdermal gel; CBD; CBD transdermal gel; Synthetic CBD; Topical cannabidiol gel; Topical CBD gel; Transdermal CBD gel; ZYN002

Latest Information Update: 29 Jun 2017

Price : $50

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epilepsy; Fragile X syndrome; Osteoarthritis
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 26 Jun 2017 Zynerba Pharmaceuticals completes enrolment in the phase II FAB-C trial for Fragile X syndrome in USA
  • 14 Mar 2017 Zynerba Pharmaceuticals completes enrolment in its phase II trial for Osteoarthritis in Australia
  • 13 Mar 2017 Zynerba Pharmaceuticals completes enrolment in its phase II STAR1 trial for Epilepsy in Australia and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top